Progress of targeted drugs for treatment of diffuse large B-cell lymphoma
10.3760/cma.j.cn115356-20221230-00364
- VernacularTitle:靶向药物治疗弥漫大B细胞淋巴瘤研究进展
- Author:
Jiajin WU
1
;
Lingyan PING
;
Jun ZHU
;
Yuqin SONG
Author Information
1. 北京大学肿瘤医院暨北京市肿瘤防治研究所淋巴肿瘤内科 恶性肿瘤发病机制及转化研究教育部重点实验室，北京 100142
- Keywords:
Lymphoma, large B-cell, diffuse;
Treatment;
Gene targeting
- From:
Journal of Leukemia & Lymphoma
2023;32(3):143-146
- CountryChina
- Language:Chinese
-
Abstract:
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of aggressive lymphoma. The relapsed/refractory DLBCL patients have poor outcomes and DLBCL is still lack of effective treatment standard regimens. How to effectively treat relapsed/refractory DLBCL patients has become a research hotspot, and the current treatment methods include bispecific antibody therapy, chimeric antigen receptor T-cell (CAR-T) therapy, antibody-drug conjugates (ADC) therapy. This paper reviews the progress of targeted drugs/cell treatment for DLBCL at the 64th American Society of Hematology annual meeting.
